Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo.

Edwards CM, Lwin ST, Fowler JA, Oyajobi BO, Zhuang J, Bates AL, Mundy GR
Am J Hematol. 2009 84 (5): 268-72

PMID: 19296472 · PMCID: PMC2753224 · DOI:10.1002/ajh.21374

The proteasome inhibitor bortezomib has a striking clinical benefit in patients with multiple myeloma. It is unknown whether the bone marrow microenvironment directly contributes to the dramatic response of myeloma cells to proteasome inhibition in vivo. We have used the well-characterized 5TGM1 murine model of myeloma to investigate myeloma growth within bone and response to the proteasome inhibitor bortezomib in vivo. Myeloma cells freshly isolated from the bone marrow of myeloma-bearing mice were found to have an increase in proteasome activity and an enhanced response to in vitro proteasome inhibition, as compared with pre-inoculation myeloma cells. Treatment of myeloma-bearing mice with bortezomib resulted in a greater reduction in tumor burden when the myeloma cells were located within the bone marrow when compared with extra-osseous sites. Our results demonstrate that myeloma cells exhibit an increase in proteasome activity and an enhanced response to bortezomib treatment when located within the bone marrow microenvironment in vivo.

MeSH Terms (17)

Animals Bone Marrow Bone Marrow Cells Boronic Acids Bortezomib Cell Communication Cell Line, Tumor Enzyme Activation Immunoglobulin G Mice Multiple Myeloma Neoplasm Transplantation Protease Inhibitors Proteasome Endopeptidase Complex Proteasome Inhibitors Pyrazines Tumor Burden

Connections (1)

This publication is referenced by other Labnodes entities:

Links